NCT05105035View on ClinicalTrials.gov

Oral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Treatment of Melioidosis in Hospitalized Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

June 14, 2022

Primary Completion Date

October 10, 2023

Study Completion Date

October 10, 2023

Conditions
Melioidosis
Interventions
DRUG

Ceftazidime or meropenem

Patients will be prescribed ceftazidime or meropenem intravenously as per standard of care for at least 14 days while in the hospital

DRUG

ARV-1801

Patients will be prescribed ARV-1801 at 1500mg 12 hours apart on Day 1 and 600mg every 12 hours for Days 2-14.

DRUG

Placebo

Patients will be prescribed placebo every 12 hours for Days 1-14.

Trial Locations (5)

41000

Udon Thani Hospital, Udon Thani

Unknown

Maharat Nakhonratchasima Hospital, Nai Muang

Srinagarind Hospital, Khon Kaen University, Nai Muang

Sunpasitthiprasong Hospital, Nai Muang

Surin Hospital, Nai Muang

Sponsors

Lead Sponsor

Arrevus Inc.

Collaborators (1)

Arnasi Group
All Listed Sponsors
collaborator

Arnasi Group

UNKNOWN

lead

Arrevus Inc.

INDUSTRY

NCT05105035 - Oral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Treatment of Melioidosis in Hospitalized Patients | Biotech Hunter | Biotech Hunter